XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
EXAGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$7.43−0.29 (-3.76%)
Close on Oct 19, 2026
- Market cap
- $179.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.11 (−35.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
EXAGEN INC. grew revenue 20.8% to $71.12M over the twelve months to Jun 30, 2026. Free cash flow was -$7.59M.
Revenue
$71.12M
+20.8% vs. a year earlier
Operating income
-$13.21M
TTM Q2 2026
Free cash flow
-$7.59M
TTM Q2 2026
EPS, diluted
-$0.81
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $179.54M
- P/E ratio
- –
- Price to sales
- 2.52
- Price to book
- 14.70
- Dividend yield
- –
- Free cash flow yield
- -4.23%
Fundamentals
- Revenue
- $71.12M
- Net income
- -$18.92M
- EPS, diluted
- -$0.81
- Free cash flow
- -$7.59M
- Book value per share
- $0.51
- Diluted shares
- 24M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$71.12M+20.8% YoY
Gross profit
$41.70M+19.2% YoY
Operating income
-$13.21M
Net income
-$18.92M
EPS, diluted
-$0.81
Free cash flow
-$7.59M
Reported periodTrailing twelve months